11 results about "Biosynthetic enzyme" patented technology

The present invention provides a composition having excellent control efficacy against plant diseases and a method for controlling plant diseases. A composition for controlling a plant disease comprising a compound represented by formula (I)[wherein each symbol represents the same definition as described in the present description] and one or more sterol biosynthetic enzyme inhibitor(s) selected from Group B has excellent control effects on plant diseases; Group B: a group consisting of prothioconazole and mefentrifluconazole.

The invention provides an S-adenosine homocysteine (SAH) analogue, an S-adenosine-L-methionine (SAM) analogue and application thereof. The preparation method comprises the following steps: synthesis of the SAH analogue and a fluoroalkyl SAM analogue, fluoromethylation modification of bioactive molecules by an HMT-MT cyclase cascade reaction system based on the fluoroalkyl SAM analogue, and construction of a fluoro derivative of a clinical drug synthesized by a one-pot enzymatic method. The SAH analogue adopted by the invention can effectively avoid spontaneous degradation of the corresponding SAM analogue, and is used for constructing a cascade reaction system based on HMT-MT cyclase, so that the yield of a fluoromethylation product is increased; it is confirmed that the fluoro-intermediate generated by MT can be accepted by downstream biosynthetase, so that a fluoro-derivative of a clinical drug synthesized by a one-pot enzymic method is constructed.

The present invention discloses a composition for improving cognitive function using a single or complex extract of Acanthopanax koreanum, Astragalus membranaceus, and / or Momordica charantia. The composition increases, in an in-vitro efficacy test, the cell viability of SH-SY5Y cells, which are human-derived neuroblastomas treated with scopolamine that is an oxidative stress-inducing drug, increases the expression of an apoptosis inhibition-related biomarker (Bcl-2), an autophagy-enhancing biomarker (Beclin-1), and an acetylcholine biosynthesis-related enzyme (ChAT), which are neurotransmitters, also increases the expression of the antioxidant-related biomarker HO-1, and increases the inactivation of GSK-3β, which is a therapeutic target for Alzheimer's disease, and furthermore, even in an in-vivo efficacy test, increases the expression of Bcl-2, Beclin-1, ChAT, and HO-1 in the hippocampus and cerebrum of an animal model with reduced cognitive function and memory induced by administration of scopolamine, and inhibits the expression of iNOS, which is an enzyme involved in NO biosynthesis that induces tissue damage.

To provide a technique for inducing early flowering of a gramineous plant.SOLUTION: The method for inducing early flowering comprises culturing a gramineous plant (e.g. rice variety'Kyo no Yume') having a functionally deficient mutation of a gene encoding gibberellin biosynthetic enzyme protein GA3ox2 under gibberellin treatment and a method for inducing early flowering of the gramineous plant comprising gibberellin is provided.SELECTED DRAWING: Figure 3

The invention relates to the technical field of microorganisms, and discloses recombinant yeast for efficiently synthesizing a GPP derivative compound as well as a construction method and application of the recombinant yeast. The recombinant yeast strain takes a yeast strain as an original strain, and is obtained by introducing a target coding gene into a cell nucleus; the target coding gene comprises a coding gene of a mevalonic acid (MVA) synthetic pathway enzyme, a coding gene of a farnesyl diphosphate synthase mutant and a coding gene of optional geranyl diphosphate derivative synthase. According to the invention, an MVA pathway and a key enzyme are introduced into a cell nucleus, so that competitive consumption of a sterol synthesis pathway in cytoplasm on geranyl diphosphate (GPP) is effectively avoided, and efficient synthesis of the GPP derivative compound is realized. Besides, the recombinant yeast strain disclosed by the invention can be combined with a reported peroxisome platform to construct a double-organelle platform strain, so that the yield of GPP derivative compounds can be further increased.

The present invention relates to methods of producing compounds of interest in a recombinant microorganism. In particular, the present invention relates to using a recombinant microorganism comprising a heterologous nucleic acid encoding one or more mycosporine-like amino acid (MAA) biosynthetic enzymes (e.g., MysH) to produce compounds of interest. Compositions comprising compounds produced using such methods are also provided herein. The present disclosure also provides methods of preventing sunburn, cancer, and chronic inflammatory diseases by administering such compositions to subjects in need thereof.

The present application relates to a kind of doped Holoferritin nanoenzymes and its biosynthesis method and application, belong to the cross technical field of nanobiology, biosynthetic enzyme, the doped Holoferritin nanoenzymes except with the protein basic characteristic of Holoferritin nanoenzymes, also have class oxidase activity and class peroxidase activity, can improve the problem of current ferritin cavity doping scheme difficulty, catalytic activity single, in complex or specific catalytic scene with application potential.

This invention belongs to the field of synthetic biology and discloses tetracycline compounds modified with a polysaccharide group at the C8 position, their biosynthetic methods, and applications. The tetracycline compounds with a polysaccharide group modification at the C8 position provided by this invention have a novel structure; the trisaccharide and hexasaccharide groups present at the C8 position are not found in known tetracycline natural products or tetracycline skeleton antibiotics. The biosynthetic method involves using a polysaccharide group derived from *Streptomyces rubrum*. ech Gene clusters, in which mis This invention expresses the gene cluster in the *Streptomyces micranthum* host, fully utilizing the different biosynthetic enzymes contained in two similar but different tetracycline natural product biosynthetic gene clusters to synthesize novel compounds that neither host bacterium can synthesize. These compounds exhibit significant inhibitory activity against *Staphylococcus aureus*, *Enterococcus faecalis*, and *Enterococcus faecium*. This invention provides new candidate compounds for the innovative development of tetracycline-based antibacterial drugs and is of great significance to the development of microbial drug resources.

To provide a method for screening a DNA sequence by which the optimum combination of the expression intensities of individual genes can readily be found even when the optimum combination of the expression intensities of the individual genes in a cluster containing a plurality of genes encoding a multimodule type biosynthetic enzyme is unknown.SOLUTION: The method for screening a DNA sequence of the present invention comprises at least the steps of: (a) assembling DNA fragments using the OGAB method to prepare a plasmid containing a plurality of DNA fragments encoding multimodular biosynthetic enzymes; (b) transforming the plasmid into a host cell to allow the host cell to produce the multimodular biosynthetic enzymes; and (c) screening a plasmid containing a DNA fragment based on the properties of the produced multimodular biosynthetic enzymes or the properties of the transformed host cell.SELECTED DRAWING: None

The invention relates to the field of gene engineering, in particular to saccharomyces cerevisiae gene engineering bacteria for producing verbascoside and echinacoside through de novo synthesis and application of the saccharomyces cerevisiae gene engineering bacteria. The genetically engineered bacterium contains a coded chorismate synthase mutant, a chorismate mutase mutant, shikimic acid kinase, cytochrome b5, glucose-6-phosphate-dehydrogenase, aromatic acetaldehyde synthase, UDP (User Datagram Protocol) glucosyltransferase, tyrosine ammonia lyase, phenylalanine ammonia lyase, cinnamate hydroxylase, 4-coumaric acid: coenzyme A ligase and acyltransferase. The invention relates to a gene encoding a UDP glucosyltransferase mutant, and more preferably, the gene encoding the UDP glucosyltransferase mutant comprises genes of a UDP glucosyltransferase mutant, a UDP glucosyltransferase mutant, a UDP glucosyltransferase mutant and a UDP glucosyltransferase mutant. Under a shake flask condition, verbascoside produced by the strain reaches 231 mg / L, echinacoside produced by the strain reaches 184 mg / L, and the strain has industrial application potential.

The application discloses a preparation process of high-activity supramolecular assembly microspheric PDRN and belongs to the field of cosmetic raw material preparation, and contains two stages of PDRN biosynthesis-enzymatic decoupling extraction refinement and supramolecular assembly microspherization. First, PDRN precursors are synthesized through fermentation of genetically engineered Escherichia coli, combined with salmon testis enzyme-assisted extraction, and purified through macroporous resin-ultrafiltration membrane combination to obtain high-purity PDRN pure product; then, through intermolecular hydrogen bonds and hydrophobic interaction, self-assembly is realized by using amphiphilic cyclodextrin derivatives and PEG-PLA as carriers to realize PDRN microspherization, and a crosslinking agent is not needed in the whole process. The prepared microspheric PDRN has a purity of 95%, a particle size of 100-300 nm, an encapsulation rate of 85%, an activity retention rate of 90%, excellent sustained release and stability, no skin irritation, and is suitable for various cosmetic formulations, and the process equipment is conventional, easy to be industrialized, the raw material utilization rate is high, and the process is green and environmentally-friendly.